Stock Market Recap: Lyra Therapeutics Inc (LYRA) Concludes at 0.27, a -1.03 Surge/Decline

For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

After finishing at $0.27 in the prior trading day, Lyra Therapeutics Inc (NASDAQ: LYRA) closed at $0.27, down -1.03%. In other words, the price has decreased by -$1.03 from its previous closing price. On the day, 1.55 million shares were traded. LYRA stock price reached its highest trading level at $0.2795 during the session, while it also had its lowest trading level at $0.2611.

Ratios:

Our goal is to gain a better understanding of LYRA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.78 and its Current Ratio is at 4.78. In the meantime, Its Debt-to-Equity ratio is 0.49 whereas as Long-Term Debt/Eq ratio is at 0.43.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on May 07, 2024, Downgraded its rating to Hold and sets its target price to $0.50 from $10 previously.

On May 07, 2024, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $12 to $2.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 10 ’23 when Waksal Harlan bought 25,000 shares for $2.96 per share. The transaction valued at 74,095 led to the insider holds 261,966 shares of the business.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LYRA now has a Market Capitalization of 16411751 and an Enterprise Value of -32846260. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.77 while its Price-to-Book (P/B) ratio in mrq is 0.21. Its current Enterprise Value per Revenue stands at -19.551 whereas that against EBITDA is 0.459.

Stock Price History:

The Beta on a monthly basis for LYRA is -0.00, which has changed by -0.917737 over the last 52 weeks, in comparison to a change of 0.2553556 over the same period for the S&P500. Over the past 52 weeks, LYRA has reached a high of $6.79, while it has fallen to a 52-week low of $0.25. The 50-Day Moving Average of the stock is -74.39%, while the 200-Day Moving Average is calculated to be -92.65%.

Shares Statistics:

The stock has traded on average 3.83M shares per day over the past 3-months and 2558190 shares per day over the last 10 days, according to various share statistics. A total of 57.21M shares are outstanding, with a floating share count of 46.09M. Insiders hold about 24.39% of the company’s shares, while institutions hold 61.99% stake in the company. Shares short for LYRA as of 1718323200 were 1547959 with a Short Ratio of 0.40, compared to 1715731200 on 603031. Therefore, it implies a Short% of Shares Outstanding of 1547959 and a Short% of Float of 3.2300000000000004.

Most Popular